Accelerate Diagnostics Announces a Successful Completion of its WAVE(TM) Pre-Clinical Trial

Stock Information for Altisource Asset

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Altisource Asset

Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets
Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results
Accelerate Diagnostics Reports Third Quarter 2024 Financial Results
Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results
Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc(TM) System
Accelerate Diagnostics Reports Second Quarter 2024 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.